Avantax Advisory Services’s ADMA Biologics ADMA Stock Holding History

Avantax Advisory Services’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$2.02M	Buy	111,176 +2,849	+3%	+$58.1K	0.01%	793
2025 Q1	$2.15M	Buy	108,327 +1,954	+2%	+$33.8K	0.01%	703
2024 Q4	$1.82M	Buy	106,373 +8,109	+8%	+$153K	0.01%	752
2024 Q3	$1.96M	Sell	98,264 -7,889	-7%	-$123K	0.01%	706
2024 Q2	$1.19M	Buy	106,153 +183	+0.2%	+$1.53K	0.01%	893
2024 Q1	$699K	Hold	105,970	–	–	0.01%	895
2023 Q4	$479K	Hold	105,970	–	–	﹤0.01%	1008
2023 Q3	$379K	Sell	105,970 -650	-0.6%	-$2.5K	﹤0.01%	1065
2023 Q2	$393K	Sell	106,620 -7,000	-6%	-$25.9K	﹤0.01%	1045
2023 Q1	$376K	Sell	113,620 -13,500	-11%	-$46.7K	﹤0.01%	1032
2022 Q4	$493K	Hold	127,120	–	–	0.01%	872
2022 Q3	$309K	Hold	127,120	–	–	﹤0.01%	991
2022 Q2	$252K	Hold	127,120	–	–	﹤0.01%	1092
2022 Q1	$233K	Hold	127,120	–	–	﹤0.01%	1120
2021 Q4	$179K	Buy	127,120 +55,000	+76%	+$72.3K	﹤0.01%	1183
2021 Q3	$81K	Sell	72,120 -74,710	-51%	-$105K	﹤0.01%	1153
2021 Q2	$235K	Sell	146,830 -40	-0%	-$70	﹤0.01%	1003
2021 Q1	$260K	Buy	146,870 +35,000	+31%	+$80.1K	0.01%	868
2020 Q4	$219K	Sell	111,870 -47,500	-30%	-$99.8K	0.01%	848
2020 Q3	$383K	Buy	159,370 +7,320	+5%	+$20.1K	0.01%	909
2020 Q2	$445K	Sell	152,050 -20,000	-12%	-$57.5K	0.01%	510
2020 Q1	$495K	Buy	172,050 +37,000	+27%	+$128K	0.01%	437
2019 Q4	$540K	Hold	135,050	–	–	0.01%	448
2019 Q3	$601K	Hold	135,050	–	–	0.02%	289
2019 Q2	$523K	Buy	135,050 +35,000	+35%	+$154K	0.02%	287
2019 Q1	$379K	Buy	100,050 +35,000	+54%	+$124K	0.02%	313
2018 Q4	$156K	Buy	+65,050	New	+$322K	0.03%	388

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Avantax Advisory Services's ADMA Position: Q2 2025 in Review

Avantax Advisory Services increased its ADMA Biologics (ADMA) stake by 2.6% in Q2 2025, buying an estimated $58.1K and bringing the position to 111,176 shares worth $2.02M. The position accounts for 0.01% of the portfolio, ranked #793.

Avantax Advisory Services first reported a position in ADMA in Q4 2018 and has held it in 27 quarters since. The position peaked at $2.15M in Q1 2025. 368 funds tracked by Wall St. Rank hold ADMA as of Q2 2025.

Avantax Advisory Services held 111,176 shares of ADMA Biologics worth $2.02M as of Q2 2025.
Avantax Advisory Services bought 2,849 ADMA Biologics shares in Q2 2025, an estimated $58.1K.
ADMA Biologics made up 0.01% of Avantax Advisory Services's portfolio in Q2 2025, its #793 holding.
Avantax Advisory Services first reported a position in ADMA Biologics in Q4 2018 and has held it in 27 quarters since.
Avantax Advisory Services's ADMA Biologics position peaked at $2.15M in Q1 2025.
368 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2025.

Based on Avantax Advisory Services's 13F filing for Q2 2025, filed 8 Aug 2025.